Left ventricular assist devices (LVADs) are utilised to treat patients with heart failure, the HeartMate 3™ being an example. In this touchCARDIO interview, we speak with Dr Mandeep Mehra (Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA) to discuss the advances in LVADs and the advantages the HeartMate 3™ (HM3) LVAD holds over other LVADs.
The abstract entitled ‘5-year Survival with LVAD Therapy in MOMENTUM 3’ was presented at the European Society of Cardiology (ESC) Congress 2022, 26 – 29 August 2022.
Questions:
- Could you give us a brief overview of advances in left ventricular assist devices (LVADs) and their application in heart failure patients? (0:21)
- Please tell us a little about the HeartMate 3™ (HM3) LVAD and its advantages over other LVADs. (2:06)
Disclosures: Mandeep Mehra is a consultant for Abbott, Janssen, Mesoblast, Medtronic, Natera and Paragonix and is on the advisory board for FineHeart, Leviticus, NupulseCV and Transmedics.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ESC 2022
Access more content on Devices here and Heart Failure here
Additional Resources: Mehra MR, Goldstein DJ, Cleveland JC, et al. Five-Year Outcomes in Patients With Fully Magnetically Levitated vs Axial-Flow Left Ventricular Assist Devices in the MOMENTUM 3 Randomized Trial. JAMA. 2022; doi: 10.1001/jama.2022.16197.
